2021 - Online - In the cloud

2021 - Online - In the cloud




13:00-13:10 Welcome and introduction

Oscar Della Pasqua & Dinesh de Alwis

13:10-14:40 Keynote Lectures COVID-19

Chairs: Oscar Della Pasqua & Lutz Harnisch

13:10-13:55 France Mentré Pharmacometrics to support clinical investigation during COVID-19 pandemics
13:10-13:55 Jeremie Guedj Pharmacometrics to support clinical investigation during COVID-19 pandemics : a viral dynamics perspective
13:55-14:40 Thorsten Lehr Modeling and Simulation of SARS-CoV-2 Infections, Hospitalizations and Outcome in Germany
14:40-15:40 Social break
15:40-15:45 PAGE scientific program

Thomas Dorlo

15:45-16:45 Pharmacometrics to advance management and prevention of COVID-19

Chairs: France Mentre & Oscar Della Pasqua

15:45-16:05 Nadege Neant Modeling SARS-CoV-2 viral kinetics in hospitalized patients
16:05-16:25 Mélanie Prague Using population approach to model COVID-19 epidemics in France: estimating the burden of SARS-Cov-2 and the effects of non-pharmaceutical interventions.
16:25-16:45 Seth Robey Predictive Primates: Enabling Rapid Go/No-Go Decisions on COVID-19 Vaccine Candidates with a Predictive, Translational MBMA and Clinical Immunogenicity Data
16:45-16:55 Break
16:55-17:40 Tutorial

Chairs: Thomas Dorlo & Lutz Harnisch

16:55-17:10 Andrew Hooker Tutorial on survival analysis and its application to the assessment of competing risks in clinical data analysis.
17:10-17:40 Joachim Grevel Tutorial on application of survival analysis to the assessment of multiple state models in clinical data analysis.
17:40 Day End





12:00-13:00 Poster Session I
13:00-14:20 Lewis Sheiner Student Session 2020

Chairs: Rocio Lledo-Garcia & Monica Simeoni

13:00-13:25 Rob van Wijk Translational quantitative systems pharmacology; crossing borders between experimental and computational drug development using zebrafish as model organism
13:25-13:50 Eleni Karatza Machine-Learning for cancer treatment: Guided covariate selection for TTE models developed from real world data with a small number of patients
13:50-14:15 Vincent Chang In silico assessment of adaptive trial design for TB regimen development
14:15-14:20 Presentation Lewis Sheiner Student Session Awards 2020

Rocio Lledo-Garcia & Monica Simeoni

14:20-14:30 Announcement WCOP 2022

Paolo Denti & Stacey Tannenbaum

14:30-15:30 Social Break
15:30-16:45 Lewis Sheiner Student Session 2021

Chairs: Juan Jose Perez-Ruixo, Stacey Tannenbaum, Kayode Ogungbenro

15:30-15:55 Linda Aulin Model-based design of innovative treatment strategies to suppress antimicrobial resistance using collateral sensitivity
15:55-16:20 Marion Kerioui Bayesian modelling of individual lesions dynamics and survival to characterize response to immunotherapy cancer treatments
16:20-16:45 Anna Mc Laughlin Population quantitative systems pharmacology model of distinct CAR-T cell phenotypes and CD19-specific metabolic tumour volume reveals sources of high pharmacokinetic variability and overall survival
16:45-16:50 Presentation Lewis Sheiner Student Session Awards 2021

Juan Jose Perez-Ruixo, Stacey Tannenbaum, Kayode Ogungbenro

16:50-17:00 Break
17:00-17:40 Stuart Beal Methodology Session I

Chair: Martin Bergstrand

17:00-17:20 Alexander Janssen The Neural Mixed Effects algorithm: leveraging machine learning for pharmacokinetic modelling
17:20-17:40 James Lu Deep Learning for PK/PD and Disease Progression Time-Course Predictions using Neural-ODE
17:40 Day End





12:00-13:00 Poster Session II
13:00-13:45 Keynote Lecture

Chair: Benjamin Ribba

13:00-13:45 Vladimir Dragalin Adaptive trial designs: opportunities and challenges
13:45-13:50 Break
13:50-15:00 Oncology-dedicated to Laurent Claret

Chairs: René Bruno, Pascal Girard, Panos Macheras

13:50-14:00 In Memoriam Laurent Claret

René Bruno

14:00-14:20 Anyue Yin Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistance
14:20-14:40 Sreenath M Krishnan Multistate model for pharmacometric analyses of overall survival in anticancer treatments
14:40-15:00 René Bruno Operating characteristics of tumor growth inhibition-overall survival models to support early Phase Ib decisions: An evaluation in first-line metastatic non-small cell lung cancer patients treated with atezolizumab plus chemotherapy based on the Phase III study IMpower150
15:00-16:00 Social Break
16:00-17:00 Integrating machine learning & quantitative pharmacology

Chairs: Marylore Chenel & Justin Wilkins

16:00-16:20 Verena Gotta Personalizing hemodialysis (HD) treatment in pediatric patients with end-stage renal disease (ESRD) – application and integration of quantitative pharmacology with machine learning
16:20-16:40 Jasmine Hughes A hybrid machine learning/pharmacokinetic approach improves predictive performance in model-informed precision dosing
16:40-17:00 Diego Vera-Yunca Semi-mechanistic modeling of tumor size and overall survival including machine learning-derived tumor heterogeneity
17:00-17:05 Break
17:05-17:45 Improving decision making in drug development and clinical care

Chair: Ana Ruiz

17:05-17:25 Nicolás Marco Ariño The broad use of pharmacometrics in patient care: the case of blood transfusion and perioperative management
17:25-17:45 Estelle Yau A systematic framework for the incorporation of preclinical species data into physiologically-based pharmacokinetic models using a middle-out approach to improve the translation of drug distribution in humans
17:45 Day End





12:00-13:00 Poster Session III
13:00-14:00 Stuart Beal Methodology Session II

Chair: France Mentre

13:00-13:20 Carolina Llanos-Paez Use of item-based non-linear mixed effects model to improve confidence in Phase III clinical trial decision-making
13:20-13:40 Iris Minichmayr Beyond disease progression – Item response theory modelling to gain structural insights into disease facets underlying clinical score assessments
13:40-14:00 Alexandra Lavalley-Morelle Individual dynamic predictions in joint analysis for nonlinear marker evolution and competing risk data: application on patients admitted in Intensive Care Unit for sepsis
14:00-14:20 Break
14:20-15:30 Bacterial Diseases

Chairs: Stephan Schmidt & Charlotte Kloft

14:20-14:30 In Memoriam Hartmut Derendorf

Stephan Schmidt

14:30-14:50 Zoe Kane Development of a neonatal plasma and cerebrospinal fluid (CSF) population PK model for fosfomycin.
14:50-15:10 David Busse Body composition and drug exposure in adipose tissue are key for antibiotic dose-individualisation in obese individuals
15:10-15:30 Jérémy Seurat Combination of in vivo phage therapy data with in silico model highlights key parameters for treatment efficacy
15:30-16:15 Social Break
16:15-17:15 Other infectious & Neurological Diseases

Chair: Lena Friberg

16:15-17:35 Roeland Wasmann A pharmacometric approach to optimise Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide for children with tuberculosis
16:35-16:55 Marie Alexandre Dynamics of the humoral immune response to a two-dose heterologous vaccine regimen against Ebola virus.
16:55-17:15 João Abrantes Model-informed development of RG6102, an amyloid-targeting investigational drug with enhanced brain penetration properties
17:15-17:25 Closing Remarks

Oscar Della Pasqua & Iztok Grabnar

17:25-17:40 Audience Input PAGE 2022

Thomas Dorlo